For the twelve months ended Jun 30, 2026, Celularity Inc. reported $18.67M of revenue and -$45.86M of net income.
CELU revenue was $5.43M in fiscal Q2 2026 (ended Jun 30, 2026), down 5.3% from a year earlier and up 41.2% from the prior quarter. For the full fiscal 2025 it was $26.55M, down 51.0% from fiscal 2024. Compound annual growth was +13.2% over 5 years. It rose in 3 of the last 5 fiscal years.
CELU net income was $706.0K in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$24.52M a year earlier and down 19.2% from the prior quarter. For the full fiscal 2025 it was -$91.72M, compared with -$57.89M in fiscal 2024.
CELU diluted EPS was $0.02 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$1.02 a year earlier and up 0.0% from the prior quarter. For the full fiscal 2025 it was -$3.59, compared with -$2.64 in fiscal 2024.
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $26.55M | $54.22M | $22.77M | $17.98M | $21.34M | $14.28M | - |
| Cost of revenue | $20.07M | $14.99M | $16.02M | - | - | - | - |
| Gross profit | $6.48M | $39.23M | $6.75M | -$1.69M | $11.68M | $9.35M | - |
| Research and development | $15.03M | $17.39M | $30.46M | $78.36M | $88.35M | $52.71M | - |
| Selling, general and admin | $51.27M | $58.64M | $50.58M | $66.02M | $71.34M | $31.34M | - |
| Operating income | -$61.31M | -$38.36M | -$192.29M | -$25.60M | -$109.06M | -$151.93M | -$1.68M |
| Pre-tax income | -$91.71M | -$57.89M | -$196.28M | $14.21M | -$100.10M | -$212.93M | $6.55M |
| Income tax | $3.0K | - | $10.0K | $13.0K | $20.0K | -$4.70M | $668.2K |
| Net income | -$91.72M | -$57.89M | -$196.29M | $14.19M | -$100.12M | -$208.23M | $5.88M |
| EPS, basic | -$3.59 | -$2.64 | -$11.02 | $1.01 | -$14.90 | -$113.10 | $1.00 |
| EPS, diluted | -$3.59 | -$2.64 | -$11.02 | $0.95 | -$14.90 | -$113.10 | $1.00 |
| Diluted shares | 25.6M | 21.9M | 17.8M | 15.0M | 6.7M | 1.8M | 2.6M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $6.17M | $10.98M | $10.16M | $28.80M | $52.08M | $69.51M | $43.51M |
| Receivables | $4.65M | - | - | - | - | - | - |
| Inventory | $571.0K | $5.41M | $5.75M | $5.31M | $9.55M | $9.55M | - |
| Current assets | $12.32M | $20.56M | $19.79M | $33.50M | $59.10M | $72.16M | $1.01M |
| Goodwill | $7.35M | $7.35M | $7.35M | $119.69M | $123.30M | $123.30M | $127.07M |
| Total assets | $107.33M | $132.68M | $143.89M | $401.07M | $414.13M | $431.01M | $291.61M |
| Current liabilities | $80.76M | $53.68M | $67.30M | $62.09M | $26.23M | $26.68M | $229.1K |
| Short-term debt | - | - | $39.24M | $37.60M | - | - | - |
| Long-term debt | $33.81M | - | - | - | - | - | - |
| Total debt | $33.81M | - | - | - | - | - | - |
| Total liabilities | $145.39M | $123.84M | $102.93M | $202.16M | $314.71M | $412.30M | $28.21M |
| Shareholders' equity | -$38.06M | $8.84M | $40.96M | $198.90M | $99.42M | -$531.40M | -$327.42M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$13.25M | -$6.40M | -$38.69M | -$137.88M | -$110.10M | -$63.19M | -$1.10M |
| Capital expenditures | - | $161.0K | $1.05M | $5.24M | $6.20M | $27.83M | - |
| Free cash flow | - | -$6.56M | -$39.73M | -$143.11M | -$116.30M | -$91.03M | - |
| Investing cash flow | - | $514.0K | -$4.05M | -$5.24M | -$5.90M | -$12.81M | -$286.85M |
| Financing cash flow | $18.65M | $6.70M | $24.09M | $119.84M | $98.56M | $102.01M | $288.84M |
| Share repurchases | - | - | - | - | - | $256.0K | - |
| Stock-based compensation | - | - | $0 | - | - | - | - |
| Depreciation and amortization | $7.29M | $7.92M | $9.32M | $9.44M | $8.82M | $8.17M | - |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -51.0% | 138.1% | 26.7% | -15.7% | 49.4% | - | - |
| Gross margin | 24.4% | 72.4% | 29.7% | -9.4% | 54.8% | 65.5% | - |
| Operating margin | -230.9% | -70.7% | -844.4% | -142.4% | -511.2% | -1064.0% | - |
| Net margin | -345.4% | -106.8% | -862.0% | 79.0% | -469.3% | -1458.4% | - |
| Free cash flow margin | - | -12.1% | -174.5% | -796.2% | -545.1% | -637.5% | - |
| Return on equity | - | -655.1% | -479.2% | 7.1% | -100.7% | - | - |
| Return on assets | -85.5% | -43.6% | -136.4% | 3.5% | -24.2% | -48.3% | 2.0% |
| Current ratio | 0.15 | 0.38 | 0.29 | 0.54 | 2.25 | 2.70 | 4.40 |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.43M | $3.85M | $4.10M | $5.28M | $5.74M | $11.43M | $18.13M | $9.30M | $12.11M | $14.68M | $12.11M | $3.79M |
| Cost of revenue | $2.35M | $1.45M | $7.37M | $3.90M | $5.24M | $3.55M | $7.34M | $3.88M | $2.12M | $1.64M | $9.61M | $3.60M |
| Gross profit | $3.08M | $2.39M | -$3.27M | $1.38M | $494.0K | $7.87M | $10.79M | $5.41M | $9.99M | $13.04M | $2.50M | $184.0K |
| Research and development | $2.03M | $2.99M | $3.35M | $4.60M | $3.35M | $3.73M | $3.83M | $3.92M | $3.80M | $5.84M | -$272.0K | $5.18M |
| Selling, general and admin | $4.94M | $9.16M | $15.06M | $9.31M | $12.63M | $14.26M | $16.06M | $12.65M | $15.91M | $14.03M | $13.07M | $10.75M |
| Operating income | -$4.24M | -$10.13M | -$22.06M | -$12.90M | -$15.86M | -$10.49M | -$9.28M | -$11.53M | -$10.18M | -$7.38M | $13.31M | -$99.26M |
| Interest expense | $177.0K | $352.0K | - | - | $1.94M | $2.44M | - | - | - | - | - | - |
| Pre-tax income | $706.0K | $874.0K | -$24.36M | -$23.08M | -$24.52M | -$19.75M | -$13.29M | -$16.10M | -$6.49M | -$22.01M | $9.56M | -$93.88M |
| Income tax | - | - | - | - | - | - | - | $0 | $0 | $0 | $10.0K | $0 |
| Net income | $706.0K | $874.0K | -$24.36M | -$23.08M | -$24.52M | -$19.75M | -$13.29M | -$16.10M | -$6.49M | -$22.01M | $9.55M | -$93.88M |
| EPS, basic | $0.02 | $0.02 | -$0.85 | -$0.88 | -$1.02 | -$0.84 | -$0.58 | -$0.73 | -$0.30 | -$1.03 | $0.80 | -$4.98 |
| EPS, diluted | $0.02 | $0.02 | -$0.85 | -$0.88 | -$1.02 | -$0.84 | -$0.58 | -$0.73 | -$0.30 | -$1.03 | $0.80 | -$4.98 |
| Diluted shares | 29.3M | 30.3M | - | 26.3M | 24.0M | 23.5M | - | 22.0M | 21.8M | 21.4M | - | 18.8M |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $586.0K | $368.0K | $6.17M | $120.0K | $10.94M | $10.30M | $10.98M | $10.33M | $10.55M | $11.95M | $10.16M | $15.10M |
| Receivables | $4.68M | $4.78M | $4.65M | - | - | - | - | - | - | - | - | - |
| Inventory | $718.0K | $477.0K | $571.0K | $2.56M | $4.41M | $6.20M | $5.41M | $3.96M | $2.92M | $3.70M | $5.75M | $4.93M |
| Current assets | $6.45M | $6.30M | $12.32M | $10.60M | $17.26M | $22.08M | $20.56M | $14.50M | $17.73M | $22.86M | $19.79M | $16.50M |
| Goodwill | $7.35M | $7.35M | $7.35M | $7.35M | $7.35M | $7.35M | $7.35M | $7.35M | $7.35M | $7.35M | $7.35M | $7.35M |
| Total assets | $96.17M | $99.48M | $107.33M | $114.24M | $120.28M | $128.88M | $132.68M | $128.84M | $135.49M | $143.82M | $143.89M | $157.19M |
| Current liabilities | $59.74M | $70.58M | $80.76M | $65.31M | $69.23M | $58.69M | $53.68M | $76.17M | $67.90M | $66.04M | $67.30M | $84.63M |
| Short-term debt | - | - | - | - | $6.30M | $6.30M | - | $42.61M | $41.00M | $39.80M | $39.24M | $14.01M |
| Long-term debt | - | - | $33.81M | $35.67M | - | - | - | - | - | - | - | - |
| Total debt | - | - | $33.81M | $35.67M | - | - | - | - | - | - | - | - |
| Total liabilities | $131.70M | $134.74M | $145.39M | $134.33M | $145.78M | $134.38M | $123.84M | $111.56M | $107.68M | $112.57M | $102.93M | $126.94M |
| Shareholders' equity | -$35.53M | -$35.26M | -$38.06M | -$20.09M | -$25.50M | -$5.51M | $8.84M | $17.28M | $27.81M | $31.25M | $40.96M | $30.25M |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.11M | $1.45M | -$5.10M | -$4.16M | -$999.0K | -$2.99M | $1.59M | -$144.0K | -$3.45M | -$4.40M | -$4.34M | -$8.32M |
| Capital expenditures | - | - | - | - | - | - | $91.0K | $0 | $31.0K | $39.0K | $580.0K | $228.0K |
| Free cash flow | - | - | - | - | - | - | $1.50M | -$144.0K | -$3.48M | -$4.44M | -$4.92M | -$8.55M |
| Investing cash flow | - | - | - | - | - | - | -$1.59M | $0 | $2.14M | -$39.0K | -$580.0K | -$228.0K |
| Financing cash flow | $1.02M | -$7.34M | $11.22M | $3.48M | $1.63M | $2.32M | $643.0K | -$79.0K | -$90.0K | $6.23M | -$14.0K | $5.74M |
| Stock-based compensation | $844.0K | $1.24M | - | $471.0K | $108.0K | $2.64M | - | - | - | - | - | - |
| Depreciation and amortization | $1.54M | $1.60M | $1.80M | $1.82M | $1.83M | $1.83M | $1.88M | $1.52M | $1.54M | $2.16M | $2.30M | $1.79M |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -5.3% | -66.3% | -77.4% | -43.2% | -52.6% | -22.2% | 49.7% | 145.5% | 312.2% | 273.1% | 193.3% | -8.4% |
| Net income growth, YoY | - | - | - | - | - | - | - | - | - | - | -60.9% | - |
| EPS growth, YoY | - | - | - | - | - | - | - | - | - | - | -64.4% | - |
| Gross margin | 56.8% | 62.2% | -79.7% | 26.1% | 8.6% | 68.9% | 59.5% | 58.2% | 82.5% | 88.8% | 20.7% | 4.9% |
| Operating margin | -78.0% | -263.5% | -537.5% | -244.1% | -276.6% | -91.8% | -51.2% | -124.0% | -84.0% | -50.2% | 109.9% | -2621.7% |
| Net margin | 13.0% | 22.7% | -593.6% | -436.7% | -427.5% | -172.9% | -73.3% | -173.2% | -53.6% | -149.9% | 78.8% | -2479.6% |
| Free cash flow margin | - | - | - | - | - | - | 8.3% | -1.5% | -28.7% | -30.3% | -40.6% | -225.8% |
| Current ratio | 0.11 | 0.09 | 0.15 | 0.16 | 0.25 | 0.38 | 0.38 | 0.19 | 0.26 | 0.35 | 0.29 | 0.19 |
Source: XBRL data Celularity Inc. files with the SEC, latest filing dated Oct 20, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-10, first reported Jul 30, 2024.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| CELU | $18.67M | -58.1% | -$45.86M | -245.7% | $24.7M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |